Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer

Maria Ornella Nicoletto, Roberta Bertorelle, Lucia Borgato, Gian Luca De Salvo, Grazia Artioli, Giuseppe Lombardi, Fable Zustovich, Raffaella Marcato, Anna Parenti, Marco Montagna, Martin E. Donach

Research output: Contribution to journalArticle


Background: The aim of the study was to assess the efficacy of pegylated liposomal doxorubicin (PLD) and oxaliplatin in patients affected by relapsed epithelial ovarian cancer with a family history of BRCA and p53 mutations.Methods: Seventy-twowomen received a median of 7.5 courses of PLD at 30 to 35 mg/m 2 plus oxaliplatin at 70 mg/m 2, and associations between BRCA1/2 and TP53 status and overall survival (OS) were determined. Thirty-eight had a short platinum-free interval (PFI;

Original languageEnglish
Pages (from-to)1022-1028
Number of pages7
JournalInternational Journal of Gynecological Cancer
Issue number6
Publication statusPublished - Aug 2009



  • BRCA
  • Ovarian cancer
  • Oxaliplatin
  • P53
  • PLD

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this